VEGF R3/FLT4 hFc Chimera, Human
VEGF R3/FLT4 HFc Chimera, Human

The purity of VEGF R3/FLT4 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

VEGF R3/FLT4 HFc Chimera, Human

VEGF R3/FLT4 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

VEGF R3/FLT4 HFc Chimera, Human

Immobilized Human VEGF-C, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for VEGF R3/FLT4 hFc Chimera, Human with the EC50 of 8.9 ng/ml determined by ELISA.

VEGF R3/FLT4 HFc Chimera, Human

Immobilized VEGF R3/FLT4 hFc Chimera, Human, hFc Tag at 2 mg/ml (100 mI/well) on the plate. Dose response curve for Human VEGF-D, His Tag with the EC50 of 0.44 mg/ml determined by ELISA.

VEGF R3/FLT4 hFc Chimera, Human

Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery.
Z03968
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
VEGF R3/FLT4 (Tyr25-Ile776)
Accession # P35916-1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 111.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 135-155 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5).
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • VEGF R3/FLT4 HFc Chimera, Human
    • VEGF R3/FLT4 HFc Chimera, Human

    The purity of VEGF R3/FLT4 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • VEGF R3/FLT4 HFc Chimera, Human
    • VEGF R3/FLT4 HFc Chimera, Human

    VEGF R3/FLT4 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • VEGF R3/FLT4 HFc Chimera, Human
    • VEGF R3/FLT4 HFc Chimera, Human

    Immobilized Human VEGF-C, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for VEGF R3/FLT4 hFc Chimera, Human with the EC50 of 8.9 ng/ml determined by ELISA.

  • VEGF R3/FLT4 HFc Chimera, Human
    • VEGF R3/FLT4 HFc Chimera, Human

    Immobilized VEGF R3/FLT4 hFc Chimera, Human, hFc Tag at 2 mg/ml (100 mI/well) on the plate. Dose response curve for Human VEGF-D, His Tag with the EC50 of 0.44 mg/ml determined by ELISA.


Background
Target Background Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors.
Synonyms VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.